Editorial: The State-of-Art in Immuno-Oncology, What to Do With Glioblastoma?

Front Immunol. 2021 Oct 27:12:788733. doi: 10.3389/fimmu.2021.788733. eCollection 2021.

Authors

Xiaoteng Cui¹, Qixue Wang¹, Chunsheng Kang¹

Affiliation

¹ Lab of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory of Post-Neuroinjury Neuro-repair and Regeneration in Central Nervous System, Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.

No abstract available

Keywords: CAR T cell therapy; glioblastoma; immunotherapy; multi-target; tumor microenvironment.

Publication types

Editorial
Introductory Journal Article

MeSH terms

Allergy and Immunology / trends*
Animals
Antineoplastic Agents, Immunological / therapeutic use
Brain Neoplasms / immunology
Brain Neoplasms / pathology
Brain Neoplasms / therapy*
Diffusion of Innovation
Forecasting
Glioblastoma / immunology
Glioblastoma / pathology
Glioblastoma / therapy*
Humans
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy / trends*
Immunotherapy, Adoptive / trends
Medical Oncology / trends*
Tumor Microenvironment / immunology

Substances

Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors